Precision BioSciences Inc (DTIL) stock
DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/3058% above fair value
$7.10+0.05 (+0.71%)
Close on Nov 18, 2026Market cap $195.97MP/E –Yield –
Precision BioSciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Precision BioSciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$51.90M. For fiscal 2025 it was -$65.84M. The highest annual figure on record is -$10.85M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$65.84M | – |
| FY2024 | Dec 31, 2024 | -$58.45M | – |
| FY2023 | Dec 31, 2023 | -$84.11M | – |
| FY2022 | Dec 31, 2022 | -$45.75M | – |
| FY2021 | Dec 31, 2021 | -$10.85M | – |
| FY2020 | Dec 31, 2020 | -$87.39M | – |
| FY2019 | Dec 31, 2019 | -$71.02M | – |
| FY2018 | Dec 31, 2018 | -$51.72M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$20.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$18.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.09M | -179.1% |
| Q2 FY2023 | Jun 30, 2023 | -$21.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.84M | – |
| Q3 FY2022 | Sep 30, 2022 | $29.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$24.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.87M | -142.4% |
| Q4 FY2021 | Dec 31, 2021 | -$23.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.91M | – |
| Q2 FY2021 | Jun 30, 2021 | -$31.34M | – |
| Q1 FY2021 | Mar 31, 2021 | $68.07M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.45M | – |
| Q3 FY2020 | Sep 30, 2020 | -$22.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$25.91M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.98M | – |
| Q2 FY2019 | Jun 30, 2019 | -$16.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.91M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.91M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.05M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.31M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.45M | – |
See a number that looks wrong?